# A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia

> **NCT02435836** · PHASE3 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 631 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT02435836
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-04
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 631 (ACTUAL)
- **Why stopped:** Study terminated when aripiprazole available commercially per protocol
- **Last updated:** 2015-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02435836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02435836, "A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02435836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*